Healthcare is evolving rapidly, and so is the need for actionable insights that reflect real-world clinical practice. Traditional clinical trials offer controlled data, but they often fail to capture the complexity of patient journeys in everyday settings. This is where Real-World Evidence (RWE) steps in – reshaping how we understand treatment pathways, uncovering hidden trends, and enabling more personalized care strategies. By analyzing treatment patterns through RWE, stakeholders can validate guidelines, improve adherence, and design interventions that truly work in practice.<\/p>\n
Modern healthcare faces challenges that demand a data-first approach but faces hard-time in adoption of the same –<\/p>\n
1. Off-label usage and therapy sequencing<\/strong> 2. Fragmented data sources hindering patient journey tracking<\/strong> 3. Insufficient insights into regional and demographic treatment variations<\/strong> 4. Difficulty in assessing real-world effectiveness and safety<\/strong> To fully leverage RWE-based treatment pattern analysis for better outcome<\/p>\n 1.\u00a0\u00a0\u00a0\u00a0\u00a0 Invest in Data Integration:<\/strong> 2.\u00a0\u00a0\u00a0\u00a0\u00a0 Adopt Advanced Analytics:<\/strong> 3.\u00a0\u00a0\u00a0\u00a0\u00a0 Ensure Regulatory Alignment:<\/strong> 4.\u00a0\u00a0\u00a0\u00a0\u00a0 Promote Cross-Functional Collaboration:<\/strong> 5.\u00a0\u00a0\u00a0\u00a0\u00a0 Focus on Patient-Centric Metrics:<\/strong> RWE-based treatment pattern analysis is no longer optional – it\u2019s essential for improving patient outcomes and driving competitive advantage. By embracing integrated data strategies, advanced analytics, and collaborative models, healthcare stakeholders can move beyond assumptions and make decisions grounded in real-world practice. Organization should start building a data-first culture that turns insights into impact.<\/p>\n","protected":false},"excerpt":{"rendered":" Healthcare is evolving rapidly, and so is the need for actionable insights that reflect […]<\/p>\n","protected":false},"author":927,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[218],"tags":[439,441,438,440],"coauthors":[373,437,237],"class_list":["post-1263","post","type-post","status-publish","format-standard","hentry","category-life-sciences","tag-clinical-insights","tag-patient-journeys","tag-rwe-treatment-pattern-analysis","tag-treatment-patterns"],"acf":[],"_links":{"self":[{"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/posts\/1263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/users\/927"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/comments?post=1263"}],"version-history":[{"count":3,"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/posts\/1263\/revisions"}],"predecessor-version":[{"id":1267,"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/posts\/1263\/revisions\/1267"}],"wp:attachment":[{"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/media?parent=1263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/categories?post=1263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/tags?post=1263"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.infosys.com\/infosys-consulting\/wp-json\/wp\/v2\/coauthors?post=1263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nIn oncology and rare diseases, 20-30% of prescriptions are off-label, creating uncertainty in monitoring outcomes. RWE helps map real-world sequencing, ensuring compliance and better outcomes<\/p>\n
\nOver 60% of health systems struggle with interoperability, causing incomplete insights and ~15% revenue leakage from missed follow-ups; RWE integrates EHRs, claims, and registries into a 360\u00b0 patient view, reducing care gaps and revenue loss.<\/p>\n
\nOnly ~50% of chronic disease patients (diabetes, TB, hypertension) adhere to therapy after 1 year, with adherence varying widely across regions; RWE highlights demographic and geographic treatment gaps, helping design targeted interventions to boost adherence.<\/p>\n
\nPost-marketing studies show up to 25% of drugs demonstrate different safety\/efficacy in real-world vs. trials, risking costly withdrawals and regulatory penalties; RWE enables continuous monitoring, surfacing safety signals early and validating real-world outcomes.<\/p>\nIndustry Trends Driving Adoption<\/h5>\n
\n
Recommendations<\/h5>\n
\nCombine structured and unstructured sources for a unified view, revealing adoption trends and unmet needs.<\/p>\n
\nUse AI\/ML to uncover hidden patterns and predict outcomes, enabling smarter resource allocation and targeted trials.<\/p>\n
\nDesign RWE studies that meet FDA\/EMA standards, accelerating approvals and strengthening payer negotiations.<\/p>\n
\nAlign clinical, commercial, and data teams early to translate insights into actionable strategies.<\/p>\n
\nIncorporate adherence, quality of life, and long-term outcomes to support value-based care models.<\/p>\n